Abstract
Mutation of a conserved Asp (D98) in the rat serotonin (5HT) transporter (rSERT) to Glu (D98E) led to decreased 5HT transport capacity, diminished coupling to extracellular Na+and Cl−, and a selective loss of antagonist potencies (cocaine, imipramine, and citalopram but not paroxetine or mazindol) with no change in 5HT Km value. D98E, which extends the acidic side chain by one carbon, affected the rank-order potency of substrate analogs for inhibition of 5HT transport, selectively increasing the potency of two analogs with shorter alkylamine side chains, gramine, and dihydroxybenzylamine. D98E also increased the efficacy of gramine relative to 5HT for inducing substrate-activated currents in Xenopus laevis oocytes, but these currents were noticeably dependent on extracellular medium acidification. I–V profiles for substrate-independent and -dependent currents indicated that the mutation selectively impacts ion permeation coupled to 5HT occupancy. The ability of the D98E mutant to modulate selective aspects of substrate recognition, to perturb ion dependence as well as modify substrate-induced currents, suggests that transmembrane domain I plays a critical role in defining the permeation pathway of biogenic amine transporters.
Keywords: serotonin, monoamine, transporter, biological transport, carrier proteins, molecular structure, permeation channel, selectivity filter
The Na+- and Cl−-dependent neurotransmitter transporters play a major role in the dynamic regulation of extracellular neurotransmitter concentrations. Not including species variants, this family of transporters is composed of more than 15 distinct members, including carriers for amino acid neurotransmitters as well as the monoamines serotonin (5HT), norepinephrine (NE), epinephrine, and dopamine (DA) (Nelson, 1998). The 5HT transporter (SERT, 5HTT) is of particular clinical interest because it is a target for many antidepressants such as the tricyclic imipramine and the 5HT-selective reuptake inhibitors (SSRIs), including fluoxetine and paroxetine (Barker and Blakely, 1995;Tatsumi et al., 1997) as well as abused psychostimulants, including cocaine and the amphetamines (Rudnick and Wall, 1992; White, 1998). Initial structural inferences suggest that the biogenic amine transporters exhibit cytoplasmic NH2 and COOH tails, 12 putative transmembrane domains (TMDs), and a large extracellular loop between TMDs III and IV containing multiple sites for N-glycosylation (Nelson, 1998). Although there has been some controversy regarding this model (Bennett and Kanner, 1997; Clark, 1997), recent studies using the substituted cysteine accessibility method (SCAM) (Akabas et al., 1992;Stauffer and Karlin, 1994) have examined and supported the 12 TMD topology (Chen et al., 1998). Despite a knowledge of the primary structure of SERTs and related transporters, little data are available that define how these domains interact with substrates and antagonists.
5HT transport studies of mammalian SERTs have provided mechanistic data for the kinetics governing the translocation of organic and ionic substrates through the membrane. 5HT influx is a co-transport process coupled to the inward movement of Na+ and Cl− with a predicted stoichiometry of 1 5HT/1 Na+/1 Cl− for influx along with the countertransport of 1 K+, thus predicting a transport cycle that is electrically neutral (Rudnick et al., 1983; Gu et al., 1994; Rudnick, 1998a). However, additional ion conducting states have been associated with SERTs (Mager et al., 1994; Lester et al., 1996) as well as homologous NE (Galli et al., 1995, 1996) and DA transporters (Sonders et al., 1997). For SERTs, these conducting states include (1) a constitutive leak pathway and (2) a substrate-activated current. In Xenopus laevis oocytes expressing rat SERT (rSERT), both the SERT leak and substrate-gated currents are potentiated by medium acidification, suggesting that the transporter is also highly permeable to protons (Cao et al., 1997, 1998). Whether these ion-conducting states use a common permeation pathway and whether this pathway is shared with the pathway along which 5HT translocates is currently unknown.
The availability of cDNAs encoding SERTs provides the molecular tools necessary for a structural dissection of the transporter to identify residues or domains critical for substrate recognition and translocation, ion coupling, and antagonist blockade. In the present studies, we identified a residue in TMD I with a binary option (Asp or Gly) among the Na+- and Cl−-dependent transporters and established that reversal of this residue in either human norepinephrine transporter (NET) (D75G) or rat SERT (D98G), or several other substitutions, caused a disruption of amine transport activity. However, the rSERT mutant D98E retained significant 5HT transport activity, allowing us to explore the consequences of this more conservative substitution on substrate and antagonist recognition, ion dependence, and SERT-mediated ion flow. Our findings link determinants of 5HT, ion recognition, and nonstoichiometric ion flow, suggesting that TMD I is one of several domains that may line a common permeation pathway for permeant species transiting the membrane through biogenic amine transporters.
MATERIALS AND METHODS
Site-directed mutagenesis. Point mutations were introduced into the wild-type rSERT and hNET cDNAs by oligonucleotide-directed mutagenesis as described previously (Kunkel et al., 1987). A single-stranded uracil-containing DNA template was generated in Escherichia coli CJ236 (dut-, ung-) (Invitrogen) using R408 helper phage. Using oligonucleotides encoding the mutations, the following mutations were introduced: rSERT D98A, D98E, D98G, D98N, D98T, and hNET D75A, D75E, D75G, and D75N. Identity of the mutant cDNAs was confirmed by dideoxynucleotide sequencing using a Sequenase-II kit (United States Biochemicals) (Sanger et al., 1977). To verify the absence of additional mutations in the parental cDNAs, rescue constructs of all mutations were constructed. For the SERT mutant rescues, the XhoI/RsrII fragment containing the various D98 mutations was removed from the mutant-containing cDNAs, and the corresponding fragment from the wild-type rSERT cDNA was ligated into D98 mutant cDNAs. For the hNET mutant rescues, the ScaI fragment containing the various D75 mutations was removed from the mutant-containing cDNA, and the corresponding fragment from the wild-type hNET was ligated into the D75 mutant constructs. The rescue constructs were tested for recovery of transport activity in either [3H]5HT or [3H]NE uptake experiments. In all cases, the rescue constructs demonstrated wild-type rSERT or hNET transport activity (data not shown), confirming that the disruption of transport activity observed for the rSERT D98 and hNET D75 mutants resulted from the single mutation.
Transient expression of SERTs in mammalian cells. To directly assess transport activity of rSERT (Blakely et al., 1991a) and the rSERT D98 mutants, as well as hNET (Pacholczyk et al., 1991) and hNET mutants, transient expression of the transporters was achieved using the recombinant vaccinia virus T7 expression system in HeLa cells (Fuerst et al., 1986; Blakely et al., 1991b). The parental cDNAs, rSERT and hNET, were previously cloned into the plasmids pBluescript II KS− and pBluescript II SK+, respectively. In each case, sense RNA is transcribed by the plasmid-encoded T7 RNA polymerase promoter. HeLa cells were cultured in DMEM supplemented with 10% fetal bovine serum, 2 mml-glutamine, and 1% penicillin/streptomycin at 37°C in a humidified 5% CO2incubator. Cells plated in 24-well culture plates (100,000 cells per well) were infected with recombinant VVT7–3 vaccinia virus encoding T7 RNA polymerase at 10 plaque-forming units per cell as described (Fuerst et al., 1986; Blakely et al., 1991b). Virus infection of the cells proceeded for 30 min in serum-free Opti-MEM I containing 55 μm 2-mercaptoethanol at 37°C. After virus infection, SERT or NET cDNA constructs were transfected into virus-infected HeLa cells using liposome-mediated transfection (Lipofectin reagent) at 100 ng DNA per well at a ratio of 1 μg of DNA/3 μg of Lipofectin (mixed in Opti-MEM I/β-mercaptoethanol).
For expression in COS-7 cells, rSERT and rSERT D98E were subcloned into the XhoI/XbaI site of the mammalian expression vector pcDNA3 (Invitrogen). This construct would place SERT expression under control of the cytomegalovirus promoter suitable for expression in COS-7 cells. Parental COS-7 cells were cultured in DMEM supplemented with 10% fetal bovine serum, 2 mm glutamine, and 1% penicillin/streptomycin at 37°C in a humidified 5% CO2environment. For uptake experiments, 100,000 cells per well were plated in 24-well culture plates (Falcon) and transfected with rSERT or D98E cDNA using 100 ng/well and a 5:1 ratio of Lipofectin reagent/DNA. Medium containing DNA and Lipofectin was removed 16–18 hr after transfection and replaced with complete DMEM culture medium. Cells were used in uptake assays 48 hr later. For cell-surface biotinylation experiments, cells (200,000 cells per well) in six-well culture plates were transfected with rSERT or D98E cDNA using 2 μg DNA/well and a 5:1 ratio of Lipofectin/DNA. Medium containing DNA and Lipofectin was removed 16–18 hr after transfection and replaced with complete DMEM culture medium. Cells were used in biotinylation experiments (see below) 48 hr later.
[3H]5HT and [3H]NE transport assays. Transfected HeLa or COS-7 cells were washed with a Krebs’-Ringer’s-HEPES (KRH) buffer (120 mm NaCl, 4.7 mm KCl, 2.2 mm CaCl2, 10 mm HEPES, 1.2 mmKH2PO4, 1.2 mmMgSO4, pH 7.4). Cells were preincubated for 10 min at 37°C in KRH containing 1.8 gm/l d-glucose, and then transport assays with 10 nm [3H]-5HT (∼100 Ci/mmol; Amersham), 100 μm pargyline, and 100 μml-ascorbic acid or 40 nm[3H]NE (∼50 Ci/mmol; Amersham), 100 μm pargyline, 100 μml-ascorbic acid, and 100 μm U-0521 were performed for 10 min at 37°C. Inhibitors were added in the preincubation step. Saturation kinetics were determined using increasing concentrations of [3H]5HT with the specific activity diluted to ∼0.1 Ci/mmol with unlabeled 5HT. Uptake was terminated by three washes with ice-cold KRH buffer. The level of accumulated [3H]5HT or [3H]NE was determined either by solubilizing cells in 1% SDS and analysis by liquid scintillation spectrometry or by solubilizing directly in scintillant (Optiphase SuperMix) with direct counting of culture plate in a Wallac MicroBeta plate reader. The Na+dependence of [3H]5HT uptake was assessed in KRH buffer using isotonic replacement of NaCl with LiCl orN-methyl-d-glucamine (NMDG) with equivalent results, whereas the Cl− dependence was determined in KRH buffer with Cl− salts replaced by sodium gluconate, potassium gluconate, and calcium nitrate at molarities equivalent to those in regular KRH buffer. Nonspecific [3H]5HT transport was assessed by parallel transfections with the host plasmid pBluescript SK II(−) alone and subtracted from the total counts. Substrate Kmand antagonist Ki values were derived by nonlinear least-square fits (Kaleidagraph, Synergy Software) using either the Hill equation for a rectangular hyperbola or the four-parameter logistic equation with necessary adjustments of IC50 values for substrate concentration to determine apparent Ki values (Cheng and Prusoff, 1973). Experiments were performed in duplicate or triplicate and repeated in two to three separate assays. Means were compared using two-sided Student’s t tests (GraphPad InStat for MacIntosh, v. 2.03) or one-way ANOVA (GraphPad PRISM for Mac, v. 2.0).
[125I]RTI-55 binding. Radioligand binding experiments using [125I]RTI-55 (NEN Life Science Products; ∼2200 Ci/mmol) were performed on wild-type and mutant rSERTs to assess whether mutation-induced alterations in transport correlated with changes in ligand binding. To prepare crude membranes, HeLa cells were transfected with SERT cDNAs as described for transport assays, except that cells were plated on 150 mmculture dishes and used 12–16 hr after transfection to maximize SERT expression. Cells were washed with PBS, incubated in ice-cold hypotonic buffer (Tris-HCl 50 mm, pH 7.4, NaCl 100 mm), detached from the plates using a cell scraper, and pelleted at 1600 × g. The resulting pellet was resuspended in ice-cold Tris/NaCl buffer and centrifuged for 20 min at 20,000 ×g. The resulting pellet was resuspended with a Brinkmann polytron (5 sec, 25,000 rpm) and centrifuged for an additional 20 min at 20,000 × g. The pellet was suspended in Tris/NaCl buffer and homogenized with the polytron (10 sec, 20,000 rpm). Samples of membrane suspensions were frozen at −80°C before use. Typically, assays were performed using 1 μg (rSERT) and 10 μg (D98E) of membrane protein as determined by the Bradford protein assay (Bio-Rad) using bovine serum albumin as the standard. Saturation binding was determined in duplicate using 0.1–20 nm[125I]RTI-55 with 1 μm paroxetine used to define nonspecific binding (Kd andBmax values: wild-type rSERT 0.37 ± 0.02 nm and 5.6 ± 0.45 × 10−12mol/mg protein; D98E 3.7 ± 0.6 nm and 5.4 ± 0.35 × 10−12 mol/mg protein). In competition binding experiments, cells were incubated with increasing concentrations of antagonist before the addition of either 0.1 nm (wild-type rSERT) or 1.0 nm (D98E) [125I]RTI-55. Assay tubes were incubated for 1 hr at 22°C and filtered using a Brandel harvester through Schleicher and Schuell #32 glass fiber filters soaked in 0.5% polyethylenimine. Bound radioactivity was measured by gamma emission spectrometry.Ki values were derived by nonlinear least-square fits (Kaleidagraph, Synergy Software) using a four-parameter logistic equation with necessary adjustments of IC50 values for radioligand concentration to determine apparentKi values (Cheng and Prusoff, 1973).
Cell-surface biotinylation of SERT and NET proteins. To determine cell-surface expression levels of the wild-type rSERT, rSERT D98E, rSERT D98G, wild-type hNET, hNET D75E, and hNET D75G, cell-surface biotinylation studies using polyclonal antibodies to either rSERT or hNET for protein detection were undertaken as described previously (Melikian et al., 1996; Qian et al., 1997). Because of technical limitations regarding the use of the T7-vaccinia virus expression system for quantitative cell-surface biotinylation (Melikian et al., 1996), all cDNAs were subcloned into the mammalian expression vector pcDNA3 (Invitrogen) for transient expression in COS-7 cells. Forty-eight hours after transfection, cells were washed with cold PBS/Ca-Mg (138 mm NaCl, 2.7 mm KCl, 1.5 mm KH2PO4, 9.6 mm Na2HPO4, 1 mmMgCl2, 0.1 mm CaCl2, pH 7.3) and then treated with freshly prepared Sulfo-NHS-Biotin (sulfosuccinimidobiotin; Pierce) (1.5 mg/ml in PBS/Ca-Mg) at 4°C for 30 min. Biotinylating reagents were removed by washing with 100 mm glycine in PBS/Ca-Mg, the reaction was further quenched by incubation with 100 mm glycine for 20 min, and then cells were washed with PBS/Ca-Mg before lysis with RIPA buffer (10 mm Tris-Base, pH 7.4, 150 mm NaCl, 1 mm EDTA, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate) supplemented with protease inhibitors (1 μg/ml leupeptin, 1 μm pepstatin, 1 mg/ml soybean trypsin inhibitors, 1 mm iodoacetamide, and 250 mmPMSF) for 30 min at 4°C with constant shaking. Lysates were centrifuged at 20,000 × g for 30 min at 4°C, and supernatants were incubated with monomeric avidin beads (175 μl bead volume/1250 μl supernatant) for 1 hr at room temperature. Beads were washed four times with RIPA, and adsorbed proteins were eluted with 50 μl of 2× Laemmli loading buffer (62.5 mm Tris-HCl, pH 6.8, 20% glycerol, 2% SDS, 5% β-mercaptoethanol, and 5% bromophenol blue) for 30 min at room temperature. A fraction of total cell lysate (20 of 800 μl), lysates after incubation with avidin beads (intracellular proteins) (20 of 800 μl), the final wash (40 of 800 μl), and the entire bead eluate (50 μl) were separated by SDS-PAGE (10%), transferred for 16 hr at 150 mA onto polyvinylidene difluoride membrane, blocked with 5% nonfat dry milk in PBS/0.1% Tween-80, and immunoblotted with anti-SERT CT-2 (1:5000) (Qian et al., 1995) or anti-NET (1:5000) (Melikian et al., 1994) antibodies using 1:5000 goat anti-rabbit HRP-conjugated secondary antibody. Subsequently, blots were stripped (62.5 mm Tris-HCl, pH 6.8, 2% SDS, and 100 mm β-mercaptoethanol) for 30 min at 50°C, washed with PBS/Tween-80 twice for 10 min, reblocked with 5% dry milk for 1 hr, and probed with anti-calnexin antibody (StressGen) (1:3000) followed by goat anti-rabbit HRP-conjugated secondary antibody (1:5000). Immunoreactive bands were visualized by ECL chemiluminescent detection (Amersham) on Hyperfilm ECL (Amersham), and scanned bands were quantitated using ImageQuant (Molecular Dynamics). Multiple exposures were used to insure quantitation within the linear range of the film. Values of SERT or NET surface proteins were normalized by levels of calnexin immunoreactivity in total cell extracts and biotinylated (cell-surface) fractions compared with the total fractions to control for different expression levels of each clone.
Two-electrode voltage clamp of SERT-expressing Xenopusoocytes. The plasmids (pBluescript SK II(−)) containing the cDNAs for either wild-type rSERT (Blakely et al., 1991a) or the D98E mutant were linearized with XbaI, and cRNA was transcribed using the mMessage mMachine T7 In Vitro Transcription Kit (Ambion). Stage V and VI defolliculated oocytes were subsequently injected with 50–100 ng of either wild-type rSERT or D98E cRNA and maintained at 18°C in Ca2+-Ringer’s solution (96 mm NaCl, 2 mm KCl, 5 mmMgCl2, 5 mm HEPES, and 0.6 mm CaCl2, pH 7.6) supplemented with 1% penicillin/streptomycin (Life Technologies/BRL) and 5% horse serum (Life Technologies/BRL). Isotonic replacement of Na+with NMDG was used in the Ca2+-Ringer’s solution for experiments performed in the absence of Na+. Oocytes were used 6–8 d after cRNA injection. Resting membrane potentials for oocytes used in recording experiments ranged from −39 to −52 mV.
Two-electrode voltage-clamp was performed on SERT-expressing oocytes using an AxoClamp 2A (Axon Instruments). Voltage-clamp glass microelectrodes were filled with 3N KCl solutions and pulled to a resistance of 0.5–5 MΩ. The recording solutions used to perfuse the oocytes consisted of room temperature Ca2+-Ringer’s at pH 4.5, 5.0, 5.5, 6.0, or 7.6 as indicated in the Figure legends. Perfusion was controlled by gravity at a rate of ∼6 ml/min. Data acquisition and analysis were recorded and stored digitally (MacLab 2e interface) using MacLab v. 3.4 (AD Instruments). I–V relationships were determined using voltage-ramp protocols: oocyte membrane potential was held at −40 mV with voltage ramp (−120 to +60 mV) applied over 10 sec. [3H]5HT uptake in SERT-expressing oocytes was performed in Ca2+-Ringer’s containing 20 nm [3H]5HT, 100 μmpargyline, and 100 μml-ascorbic acid for 30 min at room temperature. Nonspecific uptake was determined by assaying uninjected or water-injected oocytes in parallel with the wild-type rSERT- and D98E-injected oocytes.
RESULTS
The conserved Asp in TMD I of the monoamine transporters is critical for transport activity and ion dependence
Transporter chimeras and species-scanning mutagenesis studies (Barker and Blakely, 1996) have identified residues within SERT TMDs I (Barker et al., 1998) and XII (Barker et al., 1994; Barker and Blakely, 1996) that participate in competitive antagonist recognition. In evaluation of a TMD I residue (Y95 in hSERT and rSERT) that participates in SERT antagonist recognition (Barker et al., 1998), we recognized that this residue was one helical turn below a biogenic amine transporter-specific acidic residue (D98 in SERTs) (Fig.1A) that had been implicated in substrate recognition (Kitayama et al., 1992). All other members of the gene family (e.g., GABA, glycine, proline transporters) possess a Gly (G) in the equivalent position, a binary option that may suggest a constrained role in transport function. Mutation of the TMD I Asp residue in the DA transporter (DAT) leads to a disruption of DA transport and cocaine analog recognition (Kitayama et al., 1992). On the basis of the proposed role of a conserved Asp residue in TMD III of adrenergic receptors for coordinating the binding of the amine side chain of catecholamines (Strader et al., 1989, 1991) and the absolute conservation of this residue in monoamine neurotransmitter transporters, Kitayama et al. (1992) hypothesized that this residue coordinates interactions with the protonated alkylamine of substrates. Lacking from the previous studies, however, is evidence of complementarity between sites mutated in the transporter and functional substitutions on substrates or antagonists that can enhance arguments for direct ligand/transporter interactions.
To test whether the conserved Asp in TMD I (Fig. 1A) plays a critical and general role in biogenic amine transporter function, we introduced several mutations at this position in both rSERT (D98) and hNET (D75). Analysis of radiolabeled neurotransmitter uptake after transient expression of SERT D98 or NET D75 mutants revealed that most mutations completely abolished transport activity, including the switch to Gly generated to mimic the natural deviation in other family members (Fig. 1B,C). The more conservative mutation D75E in hNET was also nonfunctional, but strikingly the rSERT D98E mutant retained 35–50% of wild-type rSERT activity. This retention of transport function allowed us to characterize properties of the D98E mutant that were inaccessible in the other substitutions. Thus we found that transient expression of rSERT D98E in both HeLa (data not shown) and COS-7 cells (Fig.1D, Table 1) reduced 5HT transport capacity (Vmax) by ∼50% with little or no change in the 5HT Kmvalue.
Table 1.
Drug | 5-HT uptake Ki or Km (nm unless otherwise indicated) | |
---|---|---|
rSERT | D98E | |
Paroxetine | 0.3 ± 0.09 | 0.5 ± 0.14 |
Mazindol | 272 ± 63 | 231 ± 62 |
Cocaine | 390 ± 50 | 1490 ± 601-a |
Imipramine | 38 ± 8 | 190 ± 70 |
Citalopram | 2.2 ± 0.5 | 270 ± 901-a |
5-HT1-b | 460 ± 210 | 400 ± 160 |
Na+ | 19.9 ± 2.3 mm | >100 mm1-a |
Cl− | 5.2 ± 1.6 mm | 41.3 ± 2.5 mm |
Ki and Km values for various compounds for [3H]5HT uptake in HeLa cells transiently transfected with wild-type rSERT or the D98E mutant. [3H]5HT uptake experiments were performed as described in Materials and Methods. Data represent means ± SEs from results of three experiments performed in triplicate.
p < 0.05, compared with rSERT value.
Vmax values (mol/min per cell) for 5-HT transport determined in COS-7 cells were rSERT, 5.0 ± 2.4 × 10−18 and D98E, 2.4 ± 1.2 × 10−18.
To determine whether the reduced Vmax values obtained for the D98E mutant in COS-7 cells was caused by reduced translation or surface expression of mutant transporters, immunoprecipitation and cell-surface biotinylation experiments were performed (Melikian et al., 1996; Ramamoorthy et al., 1998). All hNET and rSERT mutants were found to be synthesized at equivalent levels as assessed by immunoprecipitations of [35S]-labeled cell extracts (data not shown). Direct immunoblots of rSERT-transfected and rSERT mutant-transfected COS-7 cells validated no differences in steady-state protein levels (Fig.2A). SERT and immunoreactive proteins in COS-7 cells are revealed as two bands of 95 and 105 kDa for both the wild-type and D98E construct that are absent from vector-transfected cells. The two bands, we suspect, represent migration attributable to heterogeneous glycosylation (Qian et al., 1995), although we did not explore this in detail. Both isoforms were collected from biotinylated cell fractions that are depleted of the intracellular marker calnexin (Fig. 2A) and thus appear to be expressed on the cell surface. When normalized to total calnexin content, no change was evident in D98G surface levels, whereas a small but insignificant decrease in surface SERT protein for the D98E mutant was detected. Wild-type levels of synthesis and cell-surface expression were also seen for the hNET D75E (Fig. 2B) and D75G mutants (data not shown), demonstrating that a disruption of protein stability and/or trafficking cannot account for the loss of transport capacity observed in hNET D75 or rSERT D98 mutants.
Another property of SERTs that might be compromised by D98E and explain a loss of transport capacity is an alteration in Na+or Cl− recognition that provides for energetic coupling to drive 5HT influx. Complete substitution for Na+ using lithium or NMDG or for Cl− with gluconate and nitrate salts resulted in a full loss of 5HT transport for both SERT-transfected and SERT D98E-transfected cells (data not shown), revealing a retention of ion dependence for amine uptake. However, when we titrated Na+ with NMDG or Cl− with gluconate, we found that SERT D98E exhibited a markedly altered ion dependence (Table 1). As described previously (Rudnick and Clark, 1993;Gu et al., 1994), Na+ concentration-dependence data for rSERT could be fit to a single hyperbolic function, consistent with a 1 Na+/1 5HT coupling stoichiometry. In contrast, Na+ dependence for D98E did not saturate in an isotonic substitution range, yielding a Km value we could only estimate as ≥100 mm (vs ∼20 mmfor rSERT). Cl− dependence for either rSERT or rSERT D98E could be fit to a single hyperbolic function as reported previously (Gu et al., 1994), supportive of a 1 Cl−/1 5HT+ coupling stoichiometry. However, in rSERT D98E we found an eightfold increase in the Cl− Km value. These findings indicate that the D98E mutation compromises utilization of external Na+ and Cl− for catalyzing inward 5HT transport, effects that may explain the reduction in 5HT transport capacity in the face of little or no reduction in surface expression or alteration in 5HT Kmvalue.
D98E differentially alters antagonist potency
Pharmacological characterization of the rSERT D98E mutant by [3H]5HT transport inhibition experiments revealed selective alterations in SERT antagonist potencies (Table 1). Thus, paroxetine and mazindol potency were essentially equal at both wild-type rSERT and D98E mutant. Cocaine and imipramine exhibited a three- to fivefold reduction in potency. Of the SSRIs tested, citalopram potency was most severely affected, with a 100-fold loss of potency at the rSERT D98E mutant. We confirmed these effects using [125I] RTI-55-labeled competition binding experiments (Boja et al., 1992; Wall et al., 1993). RTI-55 is a substituted phenyltropane like cocaine, and itsKd value for binding to SERT was significantly increased at D98E (0.37 nm vs 3.7 nm) as were the Ki values of cocaine (133 ± 35 nm vs 580 ± 160 nm) and imipramine (11.2 ± 2 nm vs 94 ± 34 nm). Interestingly, in these assays 5HT displayed a sixfold loss of affinity as an inhibitor of [125I]RTI-55 binding (184 ± 40 nm vs 1160 ± 130 nm), suggesting that 5HT recognition is subject to conformational accommodations of 5HT or SERT or both under the conditions used for transport. Alternatively, kinetic terms besides 5HT binding that can influence theKm value (Rudnick, 1998b) may have been perturbed by D98E, offsetting affinity losses. [125I]RTI-55 Bmax values were equivalent for rSERT and rSERT D98E, consistent with no major loss in SERT protein expression induced by the mutation.
Selective effects of D98E on substrate recognition
The previous proposal (Kitayama et al., 1992) that amine substrate recognition involves ion pairing between the Asp side chain carboxylic acid and the positively charged amine group on amine substrates, as in G-protein-coupled amine receptors (Strader et al., 1989, 1991), suggests that mutations at D98 of rSERT might be offset by specific structural modifications of 5HT or analogs, in particular modifications of the alkylamine chain extending from the indole ring. We identified two 5HT derivatives, dimethyltryptamine (DMT) and gramine (Fig.3A), that differ only in the length of their amine-containing side chain. If the ethylamine of DMT interacts with the carboxylic acid at D98 (Fig. 3A), shortening the alkylamine chain by one carbon to yield gramine should disrupt this interaction and lead to lower potency inhibition of 5HT uptake (Fig. 3B); however, gramine should reestablish this ion pair if the carboxylic acid at D98 is lengthened by one carbon as in the D98E mutation (Fig. 3C). When the potencies of DMT and gramine for inhibition of 5HT uptake were compared at the wild-type rSERT and the D98E mutant, we found that DMT interacts with both the wild-type and mutant transporter equivalently (Fig. 3D, Table 2). The shorter-chain gramine is more than one order of magnitude weaker than DMT as a 5HT uptake inhibitor at wild-type rSERT (Fig. 3D, Table 2). Remarkably, gramine became a more potent inhibitor of 5HT uptake when tested on SERT D98E, a potency indistinguishable from DMT or 5HT at wild-type rSERT (Fig.3D, Table 2). The preference of the D98E mutant for the shorter methylamine derivative was selective in that other substitutions on the tryptamine structure (e.g., 5′-OH, indole N, alkylamine methylation) were insensitive to the increased chain length associated with the D98E mutation (Table 2). Furthermore, we sought other structures that might generalize an interaction of the alkylamine side chain with the carboxylic acid at rSERT D98. DA and its methylamine derivative dihydroxybenzylamine (DHBA) are weak inhibitors of 5HT uptake relative to the tryptamines; however, they present a similar opportunity to adjust the alkylamine side chain length by one carbon and test for a gain of function to the D98E mutation. We found that DHBA is more than one order of magnitude less potent than DA at inhibiting 5HT uptake by wild-type rSERT, whereas the two compounds are comparable in potency at the D98E mutant because of a reduced potency of DA and a gain of function for DHBA (Table 2).
Table 2.
Compound | Ki(μm) | |
---|---|---|
rSERT | D98E | |
5-Hydroxytryptamine2-a | 0.46 ± 0.21 | 0.40 ± 0.16 |
Dimethyltryptamine | 0.74 ± 0.05 | 0.44 ± 0.23 |
Gramine | 10.3 ± 2.0 | 0.81 ± 0.142-b |
Dopamine | 240 ± 57 | 830 ± 335 |
Dihydroxybenzylamine | 4100 ± 1100 | 930 ± 1102-b |
5-Methyltryptamine | 6.0 ± 0.9 | 7.1 ± 0.8 |
Tryptamine | 0.85 ± 0.1 | 0.55 ± 0.1 |
N1-isopropyltryptamine | 36 ± 6.3 | 19 ± 4.7 |
Ki values for the inhibition by various compounds of [3H]5HT uptake in COS-7 cells transiently transfected with wild-type rSERT or the D98E mutant. [3H]5HT uptake experiments were performed as described in Materials and Methods. Data represent means ± SEs from results of three to six experiments performed in triplicate.
Km values from Table1.
p < 0.05, compared with wild-type rSERT value.
rSERT D98E disrupts substrate-gated ion flow
To gain further insights into the functional impact of the D98E mutation and its interaction with tryptamine derivatives, we examined substrate-induced currents in voltage-clamped Xenopusoocytes. Electrophysiological measurements in transporter-expressing oocytes have demonstrated that substrates, but not antagonists, activate transporter-associated currents (Mager et al., 1994; Sonders et al., 1997), and we used this facet of SERT behavior instead of conventional [3H]substrate flux measurements because of the lack of commercial availability of [3H]DMT or [3H]gramine. Consistent with previous reports (Mager et al., 1994), saturating concentrations of 5HT induced an inward current at pH 7.6 in oocytes expressing the wild-type rSERT voltage clamped at −80 mV (Fig.4A). These currents are blocked by imipramine and are absent from uninjected oocytes. Surprisingly, the D98E mutant demonstrated little (<2 nA) to no measurable 5HT-induced current at pH 7.6 (Fig. 4B). This was remarkable because [3H]5HT uptake activity for the D98E mutant assayed in the same batches of oocytes used for voltage-clamp experiments was reduced only ∼40% as compared with wild-type rSERT (Fig. 4C), similar to findings in COS-7 cells. Lowering buffer pH from 7.6 enhanced both a leak current as well as 5HT-induced currents (Cao et al., 1997). We retested rSERT and D98E at pH 5.0 and found that both transporters exhibited increased leak currents (see below), and we were able to significantly increase 5HT-gated currents in the wild-type transporter (Fig.4A). Moreover, acidic medium pH allowed us to uncover substrate-gated ion flow in the SERT D98E (Fig. 4B). At pH 5.0, we confirmed that 5HT and DMT, as well as gramine, induce currents in the D98E mutant, indicating that all three compounds behave as substrates for the transporter. Consistent with this notion, imipramine (Fig. 4A,B) blocked all substrate-induced currents in D98E-injected oocytes tested at pH 5.0 and revealed an outward current presumably attributable to block of a substrate-independent inward leak (Mager et al., 1994). Thus both wild-type rSERT and rSERT D98E are expressed in the oocyte, but acidic pH is required to reveal substrate-induced currents for D98E. This does not occur because acidic pH allows substrates to permeate more readily because the shift to pH 5.0 actually diminishes 5HT transport activity more for D98E than for rSERT (Fig. 4C), suggesting that D98E perturbs the transporter’s charge movement/substrate flux ratio.
The presence of DMT- and gramine-induced currents in D98E-expressing oocytes (measured at pH 5.0) allowed us to seek evidence for a shift in gramine Km value as a transported substrate as predicted by the 5HT uptake inhibition studies reported in COS-7 cells. Thus we measured inward currents at pH 5.0 induced by increasing concentrations of gramine in oocytes expressing either wild-type rSERT or the D98E mutant (Fig. 5A). In both cases, gramine-induced currents were saturable and fit readily with single hyperbolic functions. Analyses of these fits revealed a sevenfold increase in the potency (decreased Kmvalue) for gramine-activated currents at the D98E mutant (0.3 ± 0.04 μm) as compared with wild-type rSERT (2.2 ± 0.4 μm). Thus, gramine is more potent at the D98E mutant in both 5HT transport inhibition assays and in activation of substrate-dependent ion flow. At saturating concentrations at pH 5, gramine and 5HT gated equivalent levels of whole-cell current (Imax) for the D98E mutant, whereas gramine was less efficacious than 5HT at wild-type rSERT (Fig.5B). This indicates that gramine is not only a more potent substrate for the D98E mutant, but also D98E shifts the relative efficiency of gramine to gate substrate-activated currents to a level comparable to that observed for 5HT.
A change in ion selectivity induced by rSERT D98E
The lack of detectable substrate-gated currents for the rSERT D98E mutant at pH 7.6 (Fig. 4B) despite significant 5HT uptake in unclamped oocytes and changes in charge/substrate flux ratios suggested a mutation-induced disruption in a specific aspect of 5HT-gated ionic permeation. Na+ is involved in gating inward current flow (Mager et al., 1994) and has been proposed as the major charge-carrying species in the leak pathway at neutral pH (Lin et al., 1996). Protons appear to readily permeate biogenic amine transporters in the absence of amine substrates (Sonders et al., 1997) and may also contribute to the substrate-gated current at acidic extracellular pH (Cao et al., 1997). We thus asked whether D98E alters Na+ or pH dependence or both for leak or substrate-activated currents. As described previously (Mager et al., 1994; Cao et al., 1997; Galli et al., 1997), Na+dependence of 5HT-activated inward currents was evident when NMDG was substituted for Na+ on wild-type rSERT at pH 7. 6. At pH 5.0, where 5HT-activated currents can be detected in rSERT D98E, we found a similar loss of currents on Na+substitution (Fig.6A,B). Thus, as with 5HT transport activity measured in COS-7 cells, a dependence on extracellular Na+ for gating nonstoichiometric ion flow is retained in the D98E mutant. 5HT application to rSERT-injected or rSERT D98E-injected oocytes in NMDG buffer revealed outward currents (Fig. 6A,B), consistent with Na+-independent 5HT binding to SERTs (Mager et al., 1994; Cao et al., 1997; Galli et al., 1997) and H+permeation of a leak pathway that 5HT can block (Cao et al., 1997) and that appears to be intact in the D98E mutant.
If acidic medium is required to detect substrate-activated currents for the D98E mutant in Na+ buffer, decreased pH may titrate residues that restore Na+ permeation through substrate-activated channels, or protons may simply be traversing this pathway. To explore these possibilities, leak and 5HT-gated currents carried by rSERT (Fig. 7A) and rSERT D98E (Fig. 7B) were studied in Xenopusoocytes as a function of extracellular medium pH. I–Vcurves were determined by ramp protocols during sequential perfusion with buffer (Ctrl), substrate (5HT, 5 μm), or antagonist [citalopram (Cit), 30 μm]. Initial experiments were conducted at pH 5.0 where 5HT can be shown to gate both wild-type rSERT and rSERT D98E currents (Fig. 4A,B). The application of citalopram to injected oocytes in the absence of 5HT (but not uninjected oocytes; data not shown) resulted in positive (outward) currents below −30 mV. The shapes of the subtracted I–V plots were similar comparing mutant and wild-type SERTs (data not shown). The reversal potential for these currents (ICit–ICtrl) was unmodified by the D98E mutation (wild-type rSERT −12.2 ± 5.8 mV vs D98E −6.0 ± 3.5 mV). Similarly, the effect of pH change on the reversal potential of the leak current was similar in both wild-type rSERT and the D98E mutant, with slopes of 42 mV/pH unit and 46 mV/pH unit, respectively (Fig. 7C), suggesting that protons carry a significant fraction of current in the leak pathway at pH 5.0 and confirming that H+ permeation in the absence of substrate (leak) is unperturbed by the D98E mutation.
The addition of 5HT to transporter-injected oocytes elicited inward currents at all potentials (I5HT), increasing in magnitude relative to ICtrl at negative voltages for both wild-type and rSERT D98E. When normalized for maximum current, the shape of theI5HT–ICtrl plot was similar, indicating a comparable overall voltage dependence to the substrate-activated current (data not shown). However, theI5HT profile for D98E was noticeably shifted to the right relative to I5HT for wild-type SERT (X intercept at −18 mV for SERT vs 0 mV for D98E), suggesting a change in the permeant species carrying the substrate-induced current. BecauseI5HT never becomes outward relative toICtrl (Mager et al., 1994; Galli et al., 1995;Sonders et al., 1997), this may reflect the ability of the substrate to induce an inward current at negative potentials and block outward leak currents at positive potentials. Regardless, a true reversal potential for this current (plotted asI5HT–ICtrl) cannot be calculated. However, because antagonist blocks both leak and substrate-activated currents, I5HT does intersect with ICit, defining the total composite SERT current arising from substrate occupancy. WhenI5HT–ICit was plotted as a function of pH, the reversal potential for wild-type rSERT demonstrated a 28 mV shift per pH unit change consistent with a partial contribution of H+ to 5HT-gated ion flow (Fig.7D). In contrast, the D98E mutant exhibited a 53 mV shift in reversal potential per pH unit change, a value approaching the predicted value for a pure H+-selective current (58 mV). These data suggest that acidic medium does not restore conductance of the same permeant species to D98E that define the substrate-activated current in rSERT. Rather, the acidic extracellular medium appears to provide a source of permeant ions for a channel that, like the leak pathway, is highly permeant to H+.
DISCUSSION
SERTs, like other members of the Na+-dependent transporter family, are multi-functional proteins. First identified as mediators of 5HT uptake across brain and platelet membranes, SERTs are now recognized as major targets for antidepressants and psychostimulants (Barker and Blakely, 1995). In addition to these transport-associated processes, SERTs have multiple ion channel-like conducting states (Mager et al., 1994; Lester et al., 1996; Lin et al., 1996; Galli et al., 1997) that are sensitive to competitive transport antagonists. The structural requirements for substrate recognition, antagonist selectivity and 5HT-gated ion flow are as yet largely undefined and may involve nonoverlapping determinants. Alternatively, neurotransmitter and ion permeation may share a common permeation pathway. Our data indicate that D98 in TMD I of SERT influences antagonist recognition and acts as a selectivity determinant for substrate recognition and substrate-gated ion flow, linking TMD I to cocaine and antidepressant-sensitive permeation pathways for both neurotransmitter and nonstoichiometric ion flow.
Although most mutations at the Asp residue in TMD I for NET and SERT were nonfunctional, rSERT D98E retained significant transport activity, allowing investigation into the role of Asp98 in transporter function. The unaffected potency of several transporter antagonists as well as a wild-type Km value for 5HT in the D98E mutant supports a lack of mutation-induced perturbations in SERT structure. Our major kinetic finding was reduced 5HT transport capacity (Vmax) that did not appear to arise from reduced translation or surface expression, suggesting inefficient substrate translocation. 5HT can bind to SERTs in the absence of Na+ and Cl− (Humphreys et al., 1994), but the amine does not translocate. D98E ion dependence demonstrated a shift of both Na+ and Cl− dependence to higher Kmvalues. The Na+ Km value for D98E was out of the isotonic range, making quantitative modeling of this perturbation on 5HT uptake difficult. However, using a Na+ Km value of 100 mm and the derived Cl−Km value of 40 mm, and assuming monophasic kinetics with no ion interactions, transport capacity should drop to 47% of control in our standard assay buffer (120 mm Na+, 129.1 mmCl−), reasonably close to the measured reduction in COS-7 cells. Our findings suggest that major determinants for both Na+ and Cl− coupling reside within TMD I, although we cannot rule out a mutational effect on critical contact sites that lie outside this region. In keeping with a role for TMD I in ion dependence, Mager and coworkers (1996) found disrupted Na+ transient currents from mutation of a conserved TMD I tryptophan in GAT1 (W103 in rSERT), and Chen et al. (1997a) noted a cation dependence to methanethiosulfonate inactivation of rSERT C109, a residue in the extracellular loop between TMDs I and II.
Models of β-adrenergic receptor interactions with catecholamines propose a direct coordination of the positively charged alkylamine of ligands with the negatively charged carboxylic acid of a conserved TMD III Asp (Strader et al., 1991). To support this model, Strader and coworkers (1991) found that catecholamine derivatives could compensate for mutations in the β-adrenergic receptor. Thus, mutation of the Asp (D113) in TMD III to Ser (D113S), thereby replacing the carboxylic acid with a hydroxyl group, results in mutant receptors that can be activated by ligands possessing hydrogen bond-accepting groups in place of the alkylamine side chain. Similar findings of complementarity between mutant transporters and “mutant” ligands would increase the implications that direct contacts between ligands and transporters were being evaluated through site-directed mutagenesis. In the present study, we found that the D98E mutant compensates for disruptions in potency induced by alterations in substrate structure. Thus, gramine, bearing a methylamine side chain, was significantly more potent both as an inhibitor of 5HT uptake and at activating substrate-induced currents at the mutant D98E as compared with wild-type rSERT. Although the effect was not as dramatic as that seen with gramine, the shorter-chained analog of dopamine, DHBA, showed a similar preference for D98E, suggesting that catecholamines may be coordinated similarly to indoleamines, at least by SERTs. Interestingly, Buck and Amara (1994) also have implicated TMD I in substrate recognition for DATs through chimera studies. Antagonist ([125I]RTI-55) binding studies revealed a loss of affinity for 5HT at D98E, whereas uptake studies revealed no change in the 5HT Kmvalue. The determination of the transport Kmincludes steps distal to binding, including translocation and release of substrates, and these additional steps may offset mutation-induced effects on 5HT binding. Additionally, the conditions of transport versus binding assays (e.g., 37° vs 4°C) may allow movements of either the acidic side chain on the transporter or the alkylamine chain of the substrate to accommodate 5HT. Gramine and DHBA, however, may already be in an extended conformation and require the lengthening of the acidic side chain at D98 to recover the potency seen for the ethylamines DMT and 5HT. Because the D98E mutant could promote favorable interactions between gramine with yet another residue, studies evaluating charge–charge interactions in support of this interaction are warranted.
Because D98 influences 5HT transport, we also determined whether this residue represents a critical contact site for transporter antagonists. Evidence such as protection against alkylating agents argues that competitive antagonists such as imipramine and cocaine possess mutually exclusive, overlapping binding sites with 5HT on SERT (Graham et al., 1989). However, comparisons of radioligand dissociation rates from native SERTs suggest heterogeneity in the binding of SERT antagonists and propose distinct ligand-specific contact sites (Plenge et al., 1987, 1991). For the D98E mutant, we observed a loss of affinity for cocaine as well as for the cocaine analog RTI-55, the tricyclic imipramine, and the SSRI citalopram. These effects, however, were not shared by all antagonists (e.g., mazindol, paroxetine), consistent with the existence of unique determinants of antagonist recognition. We recently linked Y95 in rSERT, located one helical turn away from D98 in TMD I, with species-specific recognition of some but not all SERT antagonists (Barker et al., 1998). In the context of our present studies, these findings support a model by which competitive antagonists can physically obstruct substrate binding sites in addition to conformational alterations arising from ligand binding (Ferrer and Javitch, 1998). Recently, Chen and coworkers (1997b), using SCAM techniques, identified both I172 and Y176 of TMD III as potential shared sites for the recognition of both 5HT and cocaine, supporting a model whereby TMDs III and I lie close together in the folded configuration of the membrane-embedded transporter.
Not only does D98 appear to dictate ligand recognition, but the D98E mutation also compromises the SERT permeation pathway for nonstoichiometric ion flow (Mager et al., 1994; Lin et al., 1996). No detectable 5HT-induced current was observed for the D98E mutant at pH 7.6. However, the D98E mutant was clearly expressed because (1) transport activity was present, (2) leak currents were intact, and (3) a shift of external pH to pH 5.0 revealed substrate-gated currents. The loss of detectable 5HT-activated current in the D98E mutant expressing oocytes at pH 7.6 could be attributed to either a mutation-induced disruption of gating mechanisms or an alteration in permeant species or both. Because 5HT and other substrates can gate ion flow at pH 5.0 and this activity still requires extracellular Na+, gating of ion flow per se appears to be intact. Single-channel analysis of SERT-conducting states has suggested that Na+ is a major current-carrying species for both 5HT-activated and the substrate-independent leak currents (Lin et al., 1996), although recent studies suggest that H+ may have significant permeability through these pathways (Cao et al., 1997; Sonders et al., 1997). Although the Na+ and Cl−Km values were elevated and can account for a loss of ion-coupled uptake capacity, this reduction in transport would not account for the D98E-induced disruption on 5HT-gated currents at neutral pH because 5HT carries a very small fraction of the total current (Mager et al., 1994; Galli et al., 1997). Because 5HT is essentially fully protonated at neutral pH, the shift to acidic pH, as argued previously by Cao and coworkers (1997), must reveal currents not by titrating 5HT but by either (1) titrating a functional group on SERT to permit cation flow disturbed by D98E or (2) increasing the driving force for H+ flow across a permeation pathway unaffected by the D98E mutation. Analysis of the pH sensitivity of the reversal potential for the leak pathways of rSERT and D98E confirms that substrate-independent ion flow at acidic pH is essentially intact in D98E. However, although the 5HT-gated current of wild-type rSERT contains other charge carriers besides H+ (and probably Na+), the D98E 5HT-gated current is essentially proton selective. This suggests that the mutation has impacted 5HT-gated ionic selectivity rather than gating per se such that Na+ is no longer the major current-carrying species. We attempted to confirm a loss of Na+influx by D98E via [22 Na] cotransport studies but found the expression levels of SERTs inadequate to achieve this measurement.
Because the D98E mutant affects the ion coupling of 5HT transport and eliminates a component of the substrate-activated conducting current, both of which involve Na+, ion selectivity in SERT channels may be determined by domains and residues that also participate in coupling 5HT permeation to ion gradients. The simplest model would involve substrate and ion flow, including H+, as routed through a common pathway whereby the D98E mutant retains the ability to pass 5HT and H+but no other ions. As discussed by Cao and coworkers (1997), the movement of protons through SERTs may involve conduction in a “water–wire” mechanism that Na+ and other cations have no access to, whereas Na+ conduction may require distinct structural elements that impact selectivity and conduction. Recent studies of Drosophila SERT currents (C. Petersen and L. DeFelice, unpublished observations) reveal anomalous mole fraction effects between Na+ and Li+ in the leak pathway that are abolished by 5HT, suggesting that the substrate itself may modify cation interactions in a common permeation pathway. Interestingly, GAT1 GABA transporters lack transmitter-gated nonstoichiometric ion flow (Mager et al., 1996), and the Gly at the position homologous to D98 in GAT1 may contribute to this biophysical distinction with biogenic amine transporters. We cannot rule out that two pathways for nonstoichiometric ion flow could be gated by 5HT, one involved with proton permeation and a second, affected by the mutation, carrying other ions (and perhaps also 5HT) that comprise the bulk of the nonstoichiometric ion flow at neutral pH. Besides a lack of positive data to support the latter model, 5HT appears to block rather than gate the leak pathway (when tested in the absence of Na+). In addition, direct single-channel recordings of substrate-independent and substrate-activated channels byLin and coworkers (1996) indicate a similar conductance for the leak and 5HT-gated permeation pathways. Whichever model is correct, D98, and by extension TMD I, clearly constrains multiple facets of SERT function including 5HT, Na+, Cl−, and antagonist recognition as well as ion permeation, effects that must be accommodated by models linking transporter structure to function. Given the conservation of the TMD I Asp in biogenic amine transporters, we suspect that our findings generalize to NETs and DATs.
Footnotes
This work was supported by National Institutes of Health Grants R01-DA07390 (R.D.B.) and F32-DA05679 (E.L.B.) and a National Alliance for Research on Schizophrenia and Depression Established Investigator Award (R.D.B.). We acknowledge the effort of Robert Gereau and Susan Taylor-Rouse (Emory University) for assistance in the generation of the SERT and NET mutants. We also thank Louis DeFelice, Aurelio Galli, Christina Petersen, and Ian Scott Ramsey for helpful discussions and critical reviews of this manuscript.
Correspondence should be addressed to Dr. Randy D. Blakely, MRBII Room 419, Center for Molecular Neuroscience, Vanderbilt School of Medicine, Nashville, TN 37232-6600.
Dr. Barker’s and Dr. Rakhshan’s present address: Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University School of Pharmacy, W. Lafayette, IN 47907.
REFERENCES
- 1.Akabas MH, Stauffer DA, Xu M, Karlin A. Acetylcholine receptor channel structure probed in cysteine-substitution mutants. Science. 1992;258:307–310. doi: 10.1126/science.1384130. [DOI] [PubMed] [Google Scholar]
- 2.Barker EL, Blakely RD. Norepinephrine and serotonin transporters: molecular targets for antidepressant drugs. In: Bloom F, Kupfer D, editors. Psychopharmacology: the fourth generation of progress. Raven; New York: 1995. pp. 321–333. [Google Scholar]
- 3.Barker EL, Blakely RD. Identification of a single amino acid, phenylalanine 586, that is responsible for high-affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol Pharmacol. 1996;50:957–965. [PubMed] [Google Scholar]
- 4.Barker EL, Kimmel HL, Blakely RD. Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands. Mol Pharmacol. 1994;46:799–807. [PubMed] [Google Scholar]
- 5.Barker EL, Perlman MA, Adkins EM, Houlihan WJ, Pristupa ZB, Niznik HB, Blakely RD. High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis: an aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol. J Biol Chem. 1998;273:19459–19468. doi: 10.1074/jbc.273.31.19459. [DOI] [PubMed] [Google Scholar]
- 6.Bennett ER, Kanner BI. The membrane topology of GAT-1, a (Na+ and Cl−)-coupled gamma-aminobutyric acid transporter from rat brain. J Biol Chem. 1997;272:1203–1210. doi: 10.1074/jbc.272.2.1203. [DOI] [PubMed] [Google Scholar]
- 7.Blakely RD, Berson HE, Fremeau RT, Jr, Caron MG, Peek MM, Prince HK, Bradley CC. Cloning and expression of a functional serotonin transporter from rat brain. Nature. 1991a;354:66–70. doi: 10.1038/354066a0. [DOI] [PubMed] [Google Scholar]
- 8.Blakely RD, Clark JA, Rudnick G, Amara SG. Vaccinia-T7 RNA polymerase expression system: evaluation for the expression cloning of plasma membrane transporters. Anal Biochem. 1991b;194:302–308. doi: 10.1016/0003-2697(91)90233-j. [DOI] [PubMed] [Google Scholar]
- 9.Boja JW, Mitchell WM, Patel A, Kopajtic TA, Carroll FI, Lewin AH, Abraham P, Kuhar MJ. High-affinity binding of RTI-55 to dopamine and serotonin transporters in rat brain. Synapse. 1992;12:27–36. doi: 10.1002/syn.890120104. [DOI] [PubMed] [Google Scholar]
- 10.Buck KJ, Amara SG. Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. Proc Natl Acad Sci USA. 1994;91:12584–12588. doi: 10.1073/pnas.91.26.12584. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Cao YW, Mager S, Lester HA. H+ permeation and pH regulation at a mammalian serotonin transporter. J Neurosci. 1997;17:2257–2266. doi: 10.1523/JNEUROSCI.17-07-02257.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Cao YW, Li MY, Mager S, Lester HA. Amino acid residues that control pH modulation of transport-associated current in mammalian serotonin transporters. J Neurosci. 1998;18:7739–7749. doi: 10.1523/JNEUROSCI.18-19-07739.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Chen JG, Liu-Chen S, Rudnick G. External cysteine residues in the serotonin transporter. Biochemistry. 1997a;36:1479–1486. doi: 10.1021/bi962256g. [DOI] [PubMed] [Google Scholar]
- 14.Chen JG, Sachpatzidis A, Rudnick G. The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding. J Biol Chem. 1997b;272:28321–28327. doi: 10.1074/jbc.272.45.28321. [DOI] [PubMed] [Google Scholar]
- 15.Chen JG, Liu-Chen S, Rudnick G. Determination of external loop topology in the serotonin transporter by site-directed chemical labeling. J Biol Chem. 1998;273:12675–12681. doi: 10.1074/jbc.273.20.12675. [DOI] [PubMed] [Google Scholar]
- 16.Cheng Y, Prusoff WH. Relationship between the inhibition constant and the concentration of inhibitor that causes 50 percent inhibition of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
- 17.Clark JA. Analysis of the transmembrane topology and membrane assembly of the GAT-1 gamma-aminobutyric acid transporter. J Biol Chem. 1997;272:14695–14704. doi: 10.1074/jbc.272.23.14695. [DOI] [PubMed] [Google Scholar]
- 18.Ferrer JV, Javitch JA. Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter. Proc Natl Acad Sci USA. 1998;95:9238–9243. doi: 10.1073/pnas.95.16.9238. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Fuerst TR, Niles E, Studier FW, Moss B. Eukaryotic transient expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci USA. 1986;83:8122–8126. doi: 10.1073/pnas.83.21.8122. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Galli A, DeFelice LJ, Duke BJ, Moore KR, Blakely RD. Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants. J Exp Biol. 1995;198:2197–2212. doi: 10.1242/jeb.198.10.2197. [DOI] [PubMed] [Google Scholar]
- 21.Galli A, Blakely RD, DeFelice LJ. Norepinephrine transporters have channel modes of conduction. Proc Natl Acad Sci USA. 1996;93:8671–8676. doi: 10.1073/pnas.93.16.8671. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Galli A, Petersen CI, deBlaquiere M, Blakely RD, DeFelice LJ. Drosophila serotonin transporters have voltage-dependent uptake coupled to a serotonin-gated ion channel. J Neurosci. 1997;17:3401–3411. doi: 10.1523/JNEUROSCI.17-10-03401.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Graham D, Esnaud H, Habert E, Langer SZ. A common binding site for tricyclic and nontricyclic 5-hydroxytryptamine uptake inhibitors at the substrate recognition site of the neuronal sodium-dependent 5-hydroxytryptamine transporter. Biochem Pharmacol. 1989;38:3819–3826. doi: 10.1016/0006-2952(89)90591-1. [DOI] [PubMed] [Google Scholar]
- 24.Gu H, Wall SC, Rudnick G. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem. 1994;269:7124–7130. [PubMed] [Google Scholar]
- 25.Humphreys CJ, Wall SC, Rudnick G. Ligand binding to the serotonin transporter: equilibria, kinetics, and ion dependence. Biochemistry. 1994;33:9118–9125. doi: 10.1021/bi00197a014. [DOI] [PubMed] [Google Scholar]
- 26.Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA. 1992;89:7782–7785. doi: 10.1073/pnas.89.16.7782. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Kunkel TA, Roberts JD, Zakour RA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 1987;154:367–382. doi: 10.1016/0076-6879(87)54085-x. [DOI] [PubMed] [Google Scholar]
- 28.Lester HA, Cao YW, Mager S. Listening to neurotransmitter transporters. Neuron. 1996;17:807–810. doi: 10.1016/s0896-6273(00)80213-5. [DOI] [PubMed] [Google Scholar]
- 29.Lin F, Lester HA, Mager S. Single-channel currents produced by the serotonin transporter and analysis of a mutation affecting ion permeation. Biophys J. 1996;71:3126–3135. doi: 10.1016/S0006-3495(96)79506-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Mager S, Min C, Henry DJ, Chavkin C, Hoffman BJ, Davidson N, Lester HA. Conducting states of a mammalian serotonin transporter. Neuron. 1994;12:845–859. doi: 10.1016/0896-6273(94)90337-9. [DOI] [PubMed] [Google Scholar]
- 31.Mager S, Kleinberger-Doron N, Keshet GI, Davidson N, Kanner BI, Lester HA. Ion binding and permeation at the GABA transporter GAT1. J Neurosci. 1996;16:5405–5414. doi: 10.1523/JNEUROSCI.16-17-05405.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Melikian HE, McDonald JK, Gu H, Rudnick G, Moore KR, Blakely RD. Human norepinephrine transporter. Biosynthetic studies using a site-directed polyclonal antibody. J Biol Chem. 1994;269:12290–12297. [PubMed] [Google Scholar]
- 33.Melikian HE, Ramamoorthy S, Tate CG, Blakely RD. Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition. Mol Pharmacol. 1996;50:266–276. [PubMed] [Google Scholar]
- 34.Nelson N. The family of Na+/Cl− neurotransmitter transporters. J Neurochem. 1998;71:1785–1803. doi: 10.1046/j.1471-4159.1998.71051785.x. [DOI] [PubMed] [Google Scholar]
- 35.Pacholczyk T, Blakely RD, Amara SG. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature. 1991;350:350–354. doi: 10.1038/350350a0. [DOI] [PubMed] [Google Scholar]
- 36.Plenge P, Mellerup ET, Honore T, Honore PL. The activity of 25 paroxetine/femoxetine structure variants in various reactions, assumed to be important for the effect of antidepressants. J Pharm Pharmacol. 1987;39:877–882. doi: 10.1111/j.2042-7158.1987.tb03121.x. [DOI] [PubMed] [Google Scholar]
- 37.Plenge P, Mellerup ET, Laursen H. Affinity modulation of [3H]imipramine, [3H]paroxetine and [3H]citalopram binding to the 5HT transporter from brain and platelets. Eur J Pharmacol. 1991;206:243–250. doi: 10.1016/s0922-4106(05)80025-2. [DOI] [PubMed] [Google Scholar]
- 38.Qian Y, Melikian HE, Rye DB, Levey AI, Blakely RD. Identification and characterization of antidepressant-sensitive serotonin transporter proteins. J Neurosci. 1995;15:1261–1274. doi: 10.1523/JNEUROSCI.15-02-01261.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Qian Y, Galli A, Ramamoorthy S, Risso S, DeFelice LJ, Blakely RD. Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. J Neurosci. 1997;17:45–57. doi: 10.1523/JNEUROSCI.17-01-00045.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Ramamoorthy S, Melikian HE, Qian Y, Blakely RD. Biosynthesis, N-glycosylation, and surface trafficking of biogenic amine transporter proteins. In: Amara SG, editor. Methods in enzymology: neurotransmitter transporters. Academic; San Diego: 1998. pp. 347–370. [DOI] [PubMed] [Google Scholar]
- 41.Rudnick G. Bioenergetics of neurotransmitter transport. J Bioenerg Biomembr. 1998a;30:173–185. doi: 10.1023/a:1020573325823. [DOI] [PubMed] [Google Scholar]
- 42.Rudnick G. Ion-coupled neurotransmitter transport: thermodynamic vs. kinetic determinations of stoichiometry. In: Amara SG, editor. Methods in enzymology: neurotransmitter transporters. Academic; San Diego: 1998b. pp. 233–247. [DOI] [PubMed] [Google Scholar]
- 43.Rudnick G, Clark J. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta. 1993;1144:249–263. doi: 10.1016/0005-2728(93)90109-s. [DOI] [PubMed] [Google Scholar]
- 44.Rudnick G, Wall SC. The molecular mechanism of “ecstasy”: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA. 1992;89:1817–1821. doi: 10.1073/pnas.89.5.1817. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Rudnick G, Talvenheimo J, Fishkes H, Nelson PJ. Sodium ion requirements for serotonin transport and imipramine binding. Psychopharmacol Bull. 1983;19:545–549. [PubMed] [Google Scholar]
- 46.Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 1977;74:5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Sonders MS, Zhu SJ, Zahniser NR, Kavanaugh MP, Amara SG. Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J Neurosci. 1997;17:960–974. doi: 10.1523/JNEUROSCI.17-03-00960.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Stauffer DA, Karlin A. Electrostatic potential of the acetylcholine binding sites in the nicotinic receptor probed by reactions of binding-site cysteines with charged methanethiosulfonates. Biochemistry. 1994;33:6840–6849. doi: 10.1021/bi00188a013. [DOI] [PubMed] [Google Scholar]
- 49.Strader CD, Sigal IS, Dixon RA. Structural basis of beta-adrenergic receptor function. FASEB J. 1989;3:1825–1832. doi: 10.1096/fasebj.3.7.2541037. [DOI] [PubMed] [Google Scholar]
- 50.Strader CD, Gaffney T, Sugg EE, Candelore MR, Keys R, Patchett AA, Dixon RA. Allele-specific activation of genetically engineered receptors. J Biol Chem. 1991;266:5–8. [PubMed] [Google Scholar]
- 51.Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340:249–258. doi: 10.1016/s0014-2999(97)01393-9. [DOI] [PubMed] [Google Scholar]
- 52.Wall SC, Innis RB, Rudnick G. Binding of the cocaine analog 2 beta-carbomethoxy-3 beta-(4-[125I]iodophenyl)tropane to serotonin and dopamine transporters: different ionic requirements for substrate and 2 beta-carbomethoxy-3 beta-(4-[125I]iodophenyl)tropane binding. Mol Pharmacol. 1993;43:264–270. [PubMed] [Google Scholar]
- 53.White FJ. Drug addiction: cocaine and the serotonin saga. Nature. 1998;393:118–119. doi: 10.1038/30105. [DOI] [PubMed] [Google Scholar]